magnetic jewelry magic - online magnetic jewelry

A new HAY FEVER breakthrough clinically proven to reduce allergy symptoms and antihistamine use. How long were symptoms reduced? Studies showed a one-year reduction. How long? Yes, one year! this medication is a lozenge taken twice daily for 21 days. this medication is non-drowsy, natural and available without a prescription. this medication is a 21 day treatment. this medication users report reductions in symptoms one year after completing the treatment without taking additional this medication. How long? Yes one year, compared to 24-hour antihistamines it''s much longer lasting. Patients known to have seasonal allergy were examined in clinical studies in five U.S. states by qualified medical doctors. Each patient was given either the real this medication or a placebo (a dummy treatment). Nobody knew who got what. Patients recorded in symptons diaries how bad their symptoms were during and after the treatment. magnetic About one year later, patients completed a second diary. 64% of the group of patients receiving this medication recorded less sneezing, runny nose and nasal congestion one year after completing the jewelry treatment in a clinical study. This compares to 35% of the placebo group.

Jay M. Symptoms not very bad. Karl L. My congestion allergies did seem to get better after several days...Marsha R. I had some better days. Erin C. I believe it helped to a certain extent. William R. Improved after 3 days. Nancy C. On day 16 I felt so much better, by day 30 allergies continued to be improved. Angel C. Background of Cyanocobalamin Treatment in Allergic Disease MECHANISM OF ACTION: Vitamin B12 is essential to cell growth and cell division. B12 is the only known molecule in the human body uses with the element cobalt. The unique properties of cobalt permit a chemical reaction that produces the rungs of the DNA ladder. These rungs are called nucleotides. magic For magnetic any human cell to divide, it must copy its own DNA. For this replication to occur, new rungs of the ladder must be provided with the help of B12.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6